Sangamo Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Sangamo Therapeutics is gedaald met een gemiddeld jaarlijks percentage van -19.1%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.3%. De inkomsten zijn daalde met een gemiddeld percentage van 0.4% per jaar.
Belangrijke informatie
-19.1%
Groei van de winst
-9.5%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | -0.4% |
Rendement op eigen vermogen | -344.6% |
Nettomarge | -257.9% |
Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts
Nov 20What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Oct 23Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Oct 21There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Aug 03Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Jul 23Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Opbrengsten en kosten
Hoe Sangamo Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Sep 24 | 52 | -135 | 45 | 0 |
30 Jun 24 | 12 | -248 | 50 | 0 |
31 Mar 24 | 19 | -328 | 50 | 0 |
31 Dec 23 | 176 | -258 | 57 | 0 |
30 Sep 23 | 201 | -250 | 63 | 0 |
30 Jun 23 | 218 | -199 | 66 | 0 |
31 Mar 23 | 241 | -127 | 66 | 0 |
31 Dec 22 | 111 | -192 | 63 | 0 |
30 Sep 22 | 112 | -178 | 62 | 0 |
30 Jun 22 | 114 | -172 | 61 | 0 |
31 Mar 22 | 113 | -176 | 62 | 0 |
31 Dec 21 | 111 | -178 | 63 | 0 |
30 Sep 21 | 109 | -181 | 64 | 0 |
30 Jun 21 | 138 | -135 | 66 | 0 |
31 Mar 21 | 131 | -124 | 67 | 0 |
31 Dec 20 | 118 | -121 | 67 | 0 |
30 Sep 20 | 147 | -76 | 65 | 0 |
30 Jun 20 | 111 | -102 | 64 | 0 |
31 Mar 20 | 107 | -96 | 61 | 0 |
31 Dec 19 | 102 | -95 | 62 | 0 |
30 Sep 19 | 74 | -118 | 61 | 0 |
30 Jun 19 | 76 | -104 | 57 | 0 |
31 Mar 19 | 80 | -90 | 54 | 0 |
31 Dec 18 | 84 | -68 | 47 | 0 |
30 Sep 18 | 71 | -63 | 40 | 0 |
30 Jun 18 | 59 | -62 | 35 | 0 |
31 Mar 18 | 46 | -58 | 30 | 0 |
31 Dec 17 | 37 | -55 | 27 | 0 |
30 Sep 17 | 32 | -51 | 23 | 0 |
30 Jun 17 | 23 | -58 | 23 | 0 |
31 Mar 17 | 19 | -72 | 22 | 0 |
31 Dec 16 | 19 | -72 | 22 | 0 |
30 Sep 16 | 20 | -76 | 22 | 0 |
30 Jun 16 | 25 | -66 | 20 | 0 |
31 Mar 16 | 30 | -52 | 20 | 0 |
31 Dec 15 | 40 | -41 | 19 | 0 |
30 Sep 15 | 45 | -31 | 19 | 0 |
30 Jun 15 | 49 | -29 | 18 | 0 |
31 Mar 15 | 51 | -24 | 17 | 0 |
31 Dec 14 | 46 | -26 | 16 | 0 |
30 Sep 14 | 38 | -30 | 16 | 0 |
30 Jun 14 | 31 | -29 | 15 | 0 |
31 Mar 14 | 28 | -27 | 14 | 0 |
31 Dec 13 | 24 | -27 | 14 | 0 |
Kwaliteitswinsten: SGMO is momenteel verliesgevend.
Groeiende winstmarge: SGMO is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SGMO is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 19.1% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van SGMO over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: SGMO is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).
Rendement op eigen vermogen
Hoge ROE: SGMO heeft een negatief Return on Equity ( -344.56% ), omdat het momenteel verliesgevend is.